33 Recruiting Studies Using Dostarlimab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Dostarlimab
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
📍 GSK Investigational Site — Plantation, Florida
Lung Cancer, Non-Small Cell
View Study & Checklist ➔Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Recurrent Endometrial Serous Adenocarcinoma
View Study & Checklist ➔Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
📍 GSK Investigational Site — Birmingham, Alabama
Neoplasms
View Study & Checklist ➔Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
📍 Canberra Hospital — Garran,
Endometrial Cancer
View Study & Checklist ➔A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
📍 GSK Investigational Site — Anchorage, Alaska
Ovarian Neoplasms
View Study & Checklist ➔Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
📍 GSK Investigational Site — Los Angeles, California
Neoplasms
View Study & Checklist ➔Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
📍 M D Anderson Cancer Center — Houston, Texas
Lung Small Cell Carcinoma
View Study & Checklist ➔Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
📍 Los Angeles General Medical Center — Los Angeles, California
Advanced Malignant Skin Neoplasm
View Study & Checklist ➔Dostarlimab and Cobolimab in Advanced Cervical Cancer
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Cervical Cancer
View Study & Checklist ➔Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
📍 Georgetown University Medical Center — Washington D.C., District of Columbia
Melanoma Stage III
View Study & Checklist ➔A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
📍 GSK Investigational Site — Los Angeles, California
Neoplasms, Rectal
View Study & Checklist ➔A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
📍 GSK Investigational Site — Phoenix, Arizona
Neoplasms
View Study & Checklist ➔Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
📍 GSK Investigational Site — Fountain Valley, California
Lung Cancer, Non-Small Cell
View Study & Checklist ➔A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
📍 GSK Investigational Site — Los Angeles, California
Melanoma
View Study & Checklist ➔Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
📍 GSK Investigational Site — Atlanta, Georgia
Multiple Myeloma
View Study & Checklist ➔Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Anatomic Stage III Breast Cancer AJCC v8
View Study & Checklist ➔A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
📍 GSK Investigational Site — New Haven, Connecticut
Neoplasms, Head and Neck
View Study & Checklist ➔Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
📍 Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
Recurrent Cervix Cancer
View Study & Checklist ➔Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
📍 Sibley Memorial Hospital — Washington D.C., District of Columbia
Breast Cancer
View Study & Checklist ➔First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
📍 GSK Investigational Site — San Francisco, California
Neoplasms
View Study & Checklist ➔Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
📍 Yale University Cancer Center — New Haven, Connecticut
Stage I Breast Cancer
View Study & Checklist ➔A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
📍 GSK Investigational Site — Ocala, Florida
Lung Cancer, Non-Small Cell
View Study & Checklist ➔Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
📍 University of Iowa Hospitals & Clinics — Iowa City, Iowa
Colon Cancer
View Study & Checklist ➔A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
📍 GSK Investigational Site — Jonesboro, Arkansas
Neoplasms, Head and Neck
View Study & Checklist ➔Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Endometrial Cancer
View Study & Checklist ➔Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
📍 Memorial Sloan Kettering Basking Ridge (All Protocol Activites) — Basking Ridge, New Jersey
Endometrial Cancer
View Study & Checklist ➔A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
📍 Princess Margaret Cancer Centre — Toronto, Ontario
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
📍 M D Anderson Cancer Center — Houston, Texas
Brain Metastases
View Study & Checklist ➔A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
📍 GSK Investigational Site — La Jolla, California
Tumours, Gynecological
View Study & Checklist ➔A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
📍 GSK Investigational Site — Stanford, California
Neoplasms
View Study & Checklist ➔Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
📍 GSK Investigational Site — Tucson, Arizona
Colonic Neoplasms
View Study & Checklist ➔Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
📍 Moffitt Cancer Center — Tampa, Florida
Penile Carcinoma
View Study & Checklist ➔Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
📍 M D Anderson Cancer Center — Houston, Texas
Ovarian Clear Cell Carcinoma
View Study & Checklist ➔